Skip to main
GKOS

Glaukos (GKOS) Stock Forecast & Price Target

Glaukos (GKOS) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 38%
Hold 0%
Sell 8%
Strong Sell 0%

Bulls say

Glaukos Corp is experiencing positive growth indicators with expectations for the Corneal Health segment to grow by 9.4% for FY26, particularly as reimbursement for Epioxa improves in the latter half of the fiscal year. The company’s iDose product line has shown strong momentum, with sales ramping up in 4Q25, contributing to a gross margin of 85.1%, which exceeds consensus estimates. Additionally, Glaukos has adjusted its FY26 revenue projections for the iDose line upward to $205 million, reflecting increased confidence due to the recent FDA approval for re-administration of iDose TR.

Bears say

Glaukos Corp reported domestic glaucoma revenue of $86 million, exceeding consensus but demonstrating a deceleration in growth rates, with a 54% increase slightly down from 57% in the previous quarter. Anticipated revenue growth for the company's key products has been revised downward due to expected headwinds in the minimally invasive glaucoma surgery (MIGS) market, particularly outside the United States and a slowdown in the U.S. market as well. The company has also lowered its adjusted earnings per share projections for 2026 and 2027, suggesting a negative outlook stemming from challenges related to market growth, product uptake, competitive pressure, and potential reimbursement changes.

Glaukos (GKOS) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Glaukos (GKOS) Forecast

Analysts have given Glaukos (GKOS) a Buy based on their latest research and market trends.

According to 13 analysts, Glaukos (GKOS) has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $134.46, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $134.46, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Glaukos (GKOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.